Long Term Neurotoxic Effects of Chemotherapy in Survivors of Bone and Soft Tissue Sarcomas. A Retrospective Study
Sarcoma, Soft Tissue, Osteosarcoma Tumor
About this trial
This is an interventional screening trial for Sarcoma, Soft Tissue
Eligibility Criteria
Inclusion criteria:
Survivors of paediatric bone or soft tissue sarcomas, who were treated from 1992 onwards in the paediatric haematooncology department of UZLeuven according to one of the following treatment protocols.
*For soft tissue sarcomas: MMT 95, MMT 98, RMS2005 or NRST2005
*For Ewing sarcoma: EICESS 92, Euro-Ewing 99 or Euro-Ewing 2008
*For osteosarcoma: EORTC 80931 or Euramos1 protocols
There will be variability in treatment regimens, but the patient group will be clustered into four subgroups:
- Cisplatin and anthracyclines
- Cisplatin, anthracyclines and methotrexate
- Alkylating agents
- Alkylating agents and anthracyclines
Exclusion criteria:
- Mental retardation documented before treatment
- Inability to perform the tests because of motor or sensory deficits
- Epilepsy
- Other cognitive disorders
- Depression
- Relapse
- Parameningeal or intracranial sarcomas
- Syndrome (e.g. Down)
- Autologous stemcell transplantation
- Head/neck/spinal radiotherapy or psychopharmaca
Sites / Locations
- UZ Leuven , pediatric oncologyRecruiting
Arms of the Study
Arm 1
No Intervention
Neuropsychological assessment, MRI
This is a cross-sectional mono-center study examining survivors who were exposed to chemotherapy for bone or soft tissue sarcomas in childhood. Survivors of bone or soft tissue sarcomas will be examined with neuropsychological tests, questionnaires and advanced MR imaging (Neuropsychological assessment, MRI). Results will be compared to a healthy control group matched for age and sex.